SINTX Technologies (SINT) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for its patent application titled, “Antipathogenic Fibrous Materials.” The patent secures broad protection for SINTX’s proprietary silicon nitride-based antipathogen platform. This allowance marks a significant intellectual property milestone for the Company, securing broad protection for the use of silicon nitride in multiple form factors designed to neutralize pathogens at the point of contact. The patent establishes a foundation for further infection-resistant innovation in medical devices, surgical care, wound management, filtration and PPE, and healthcare infrastructure – segments of a global infection-prevention market estimated to exceed $30 billion annually. This newly allowed patent positions SINTX as a unique participant across these verticals with a single enabling material.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SINT:
- Sintx Technologies Appoints New CFO Kevin Trask
- Sintx Technologies publishes study of antiviral activity of Silicon Nitride
- Sintx Technologies issues business update following strategic realignment
- Sintx expands silicon nitride platform into hybrid CFR-PEKK trauma plates
- Sintx Technologies submits FDA 510k for silicon nitride foot, ankle devices